BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 1381912)

  • 1. Immunogenicity of recombinant core particles of hepatitis B virus containing epitopes of human immunodeficiency virus 1 core antigen.
    Ulrich R; Borisova GP; Gren E; Berzin I; Pumpen P; Eckert R; Ose V; Siakkou H; Gren EJ; von Baehr R
    Arch Virol; 1992; 126(1-4):321-8. PubMed ID: 1381912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of chimeric HBc proteins with epitopes in E.coli: formation of virus-like particles and a potent inducer of antigen-specific cytotoxic immune response and anti-tumor effect in vivo.
    Zhang Y; Song S; Liu C; Wang Y; Xian X; He Y; Wang J; Liu F; Sun S
    Cell Immunol; 2007 May; 247(1):18-27. PubMed ID: 17707782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis B virus core and e antigen: immune recognition and use as a vaccine carrier moiety.
    Schödel F; Peterson D; Milich D
    Intervirology; 1996; 39(1-2):104-10. PubMed ID: 8957676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A virulent Salmonella expressing hybrid hepatitis B virus core/pre-S genes for oral vaccination.
    Schödel F; Peterson D; Hughes J; Milich DR
    Vaccine; 1993; 11(2):143-8. PubMed ID: 7679864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Principal neutralizing domain of HIV-1 is highly immunogenic when expressed on the surface of hepatitis B core particles.
    von Brunn A; Brand M; Reichhuber C; Morys-Wortmann C; Deinhardt F; Schödel F
    Vaccine; 1993; 11(8):817-24. PubMed ID: 7689283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity.
    Schödel F; Moriarty AM; Peterson DL; Zheng JA; Hughes JL; Will H; Leturcq DJ; McGee JS; Milich DR
    J Virol; 1992 Jan; 66(1):106-14. PubMed ID: 1370083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hybrid hepatitis B virus core antigen as a vaccine carrier moiety: I. presentation of foreign epitopes.
    Schödel F; Peterson D; Hughes J; Wirtz R; Milich D
    J Biotechnol; 1996 Jan; 44(1-3):91-6. PubMed ID: 8717391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B virus core-preS2 particles expressed by recombinant vaccinia virus.
    Nemecková S; Sroller V; Kunke D; Krystofová J; Kutinová L
    Acta Virol; 1996; 40(5-6):273-9. PubMed ID: 9171455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and immunoactivity of chimeric particulate antigens of receptor binding site-core antigen of hepatitis B virus.
    Yang HJ; Chen M; Cheng T; He SZ; Li SW; Guan BQ; Zhu ZH; Gu Y; Zhang J; Xia NS
    World J Gastroenterol; 2005 Jan; 11(4):492-7. PubMed ID: 15641132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
    Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
    J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between antigenicity and immunogenicity of chimeric hepatitis B virus core particles carrying HIV type 1 epitopes.
    Grene E; Mezule G; Borisova G; Pumpens P; Bentwich Z; Arnon R
    AIDS Res Hum Retroviruses; 1997 Jan; 13(1):41-51. PubMed ID: 8989426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specificity of humoral and cellular immune response against recombinant particles of nucleocapsid protein of human hepatitis B virus in rabbits.
    Isaguliants MG; Kadoshnikov YP; Kalinina TI; Smirnov VD; Wahren B
    Biochemistry (Mosc); 1998 May; 63(5):551-8. PubMed ID: 9632891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction and immunological evaluation of multivalent hepatitis B virus (HBV) core virus-like particles carrying HBV and HCV epitopes.
    Sominskaya I; Skrastina D; Dislers A; Vasiljev D; Mihailova M; Ose V; Dreilina D; Pumpens P
    Clin Vaccine Immunol; 2010 Jun; 17(6):1027-33. PubMed ID: 20410327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutated epitopes of hepatitis B surface antigen fused to the core antigen of the virus induce antibodies that react with the native surface antigen.
    Shiau AL; Murray K
    J Med Virol; 1997 Mar; 51(3):159-66. PubMed ID: 9139078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New chimaeric hepatitis B virus core particles carrying hantavirus (serotype Puumala) epitopes: immunogenicity and protection against virus challenge.
    Ulrich R; Koletzki D; Lachmann S; Lundkvist A; Zankl A; Kazaks A; Kurth A; Gelderblom HR; Borisova G; Meisel H; Krüger DH
    J Biotechnol; 1999 Aug; 73(2-3):141-53. PubMed ID: 10486924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The immunization effects of HBV core antigen and surface antigen fusion protein in mice].
    Li L; Tian YJ; Shen H; Zhao XP; Yang DL
    Zhonghua Gan Zang Bing Za Zhi; 2009 Apr; 17(4):275-9. PubMed ID: 19403026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Synthesis of hepatitis B virus core antigen (HBcAg) particles by recombinant vaccinia virus].
    Loparev VN; Araslanov RR; Mitina IV; Antonova TP; Ianova NN; Iashina TL; Chernos VI
    Mol Gen Mikrobiol Virusol; 1990 Oct; (10):18-22. PubMed ID: 1702184
    [No Abstract]   [Full Text] [Related]  

  • 18. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses.
    Jegerlehner A; Tissot A; Lechner F; Sebbel P; Erdmann I; Kündig T; Bächi T; Storni T; Jennings G; Pumpens P; Renner WA; Bachmann MF
    Vaccine; 2002 Aug; 20(25-26):3104-12. PubMed ID: 12163261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune responses to hepatitis B virus surface and core antigens in mice, monkeys, and pigs after Accell particle-mediated DNA immunization.
    Fuller JT; Fuller DH; McCabe D; Haynes JR; Widera G
    Ann N Y Acad Sci; 1995 Nov; 772():282-4. PubMed ID: 8546409
    [No Abstract]   [Full Text] [Related]  

  • 20. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.